With nothing more than a quick view of its chart and a passing glance at the headlines, it would be easy to decide Gilead Sciences, Inc. (NASDAQ:GILD) is best left avoided. The GILD stock price took a fairly big tumble after the release of its …
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it …
Owning a stock that doubles in value in less than 11 months is exciting. But what word do you use for a stock that rises to 4.5 times its original price in that amount of time? Thrilling? Exhilarating? Whatever word is the best fit, it applies to …
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder’s Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common …
* Cel-Sci Corp - a 1-for-25 reverse split was authorized for its outstanding shares of common stock Source text for Eikon: Further company coverage: Our Standards:The Thomson Reuters Trust Principles.
Reuters11mon
The surprising part is that Gilead's shares slumped last month despite the late-stage success of its next major HIV single-tablet drug regimen: a fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide indicated for the …
On June 29th, 2017, research firm Jefferies upgraded the Company's stock rating from 'Hold' to 'Buy'. Sign up for your …
symbol=TROV Shares in Raleigh, North Carolina headquartered PRA Health Sciences Inc. ended the day 0.05% higher …